X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Torrent Pharma with Cadila Healthcare - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

TORRENT PHARMA vs CADILA HEALTHCARE - Comparison Results

TORRENT PHARMA    Change

Torrent Pharmaceuticals Ltd. is the flagship company of the Torrent Group set up in 1959. Based in Ahmedabad, it was promoted by Mr U.N. Mehta initially as Trinity Laboratories Ltd. and was later renamed to its current name. The company derives its r... More

CADILA HEALTHCARE 
   Change

Cadila Healthcare is one of the leading players in the Indian pharma market having a presence in both the domestic and international markets. In the international markets, the company had adopted the strategy of competing directly in the generics mar... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    TORRENT PHARMA CADILA HEALTHCARE TORRENT PHARMA/
CADILA HEALTHCARE
 
P/E (TTM) x 45.8 17.6 259.9% View Chart
P/BV x 6.5 4.2 154.9% View Chart
Dividend Yield % 0.8 1.0 80.8%  

Financials

 TORRENT PHARMA   CADILA HEALTHCARE
EQUITY SHARE DATA
    TORRENT PHARMA
Mar-18
CADILA HEALTHCARE
Mar-18
TORRENT PHARMA/
CADILA HEALTHCARE
5-Yr Chart
Click to enlarge
High Rs1,550558 277.8%   
Low Rs1,144362 316.3%   
Sales per share (Unadj.) Rs354.7116.3 305.0%  
Earnings per share (Unadj.) Rs40.117.9 224.3%  
Cash flow per share (Unadj.) Rs64.223.1 277.6%  
Dividends per share (Unadj.) Rs14.003.50 400.0%  
Dividend yield (eoy) %1.00.8 136.6%  
Book value per share (Unadj.) Rs273.185.4 319.8%  
Shares outstanding (eoy) m169.221,023.74 16.5%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x3.84.0 96.0%   
Avg P/E ratio x33.625.7 130.6%  
P/CF ratio (eoy) x21.019.9 105.5%  
Price / Book Value ratio x4.95.4 91.6%  
Dividend payout %34.919.6 178.3%   
Avg Mkt Cap Rs m227,897470,664 48.4%   
No. of employees `00014.711.8 124.4%   
Total wages/salary Rs m11,35318,545 61.2%   
Avg. sales/employee Rs Th4,083.010,072.7 40.5%   
Avg. wages/employee Rs Th772.31,569.1 49.2%   
Avg. net profit/employee Rs Th461.31,547.7 29.8%   
INCOME DATA
Net Sales Rs m60,021119,049 50.4%  
Other income Rs m2,9881,132 264.0%   
Total revenues Rs m63,009120,181 52.4%   
Gross profit Rs m13,49328,475 47.4%  
Depreciation Rs m4,0865,388 75.8%   
Interest Rs m3,085911 338.6%   
Profit before tax Rs m9,31023,308 39.9%   
Minority Interest Rs m0628 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m2,5295,644 44.8%   
Profit after tax Rs m6,78118,292 37.1%  
Gross profit margin %22.523.9 94.0%  
Effective tax rate %27.224.2 112.2%   
Net profit margin %11.315.4 73.5%  
BALANCE SHEET DATA
Current assets Rs m52,62382,005 64.2%   
Current liabilities Rs m52,02260,720 85.7%   
Net working cap to sales %1.017.9 5.6%  
Current ratio x1.01.4 74.9%  
Inventory Days Days12073 163.5%  
Debtors Days Days7698 77.5%  
Net fixed assets Rs m85,01683,703 101.6%   
Share capital Rs m8461,024 82.6%   
"Free" reserves Rs m45,37686,421 52.5%   
Net worth Rs m46,22287,445 52.9%   
Long term debt Rs m41,11525,551 160.9%   
Total assets Rs m142,432180,653 78.8%  
Interest coverage x4.026.6 15.1%   
Debt to equity ratio x0.90.3 304.4%  
Sales to assets ratio x0.40.7 63.9%   
Return on assets %6.910.6 65.2%  
Return on equity %14.720.9 70.1%  
Return on capital %14.222.0 64.5%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m14,58042,683 34.2%   
Fx outflow Rs m3,60011,242 32.0%   
Net fx Rs m10,98031,441 34.9%   
CASH FLOW
From Operations Rs m8,9429,193 97.3%  
From Investments Rs m-47,070-9,737 483.4%  
From Financial Activity Rs m34,174515 6,635.7%  
Net Cashflow Rs m-3,655-29 12,603.4%  

Share Holding

Indian Promoters % 71.5 74.8 95.6%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 7.0 8.3 84.6%  
FIIs % 12.6 5.9 213.6%  
ADR/GDR % 0.0 0.0 -  
Free float % 8.8 11.0 80.0%  
Shareholders   26,511 44,069 60.2%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare TORRENT PHARMA With:   CIPLA  PFIZER  ALEMBIC PHARMA  SHASUN PHARMA  SANOFI INDIA  

Compare TORRENT PHARMA With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 284 Points Up; FMCG & Metal Stocks Top Gainers(Closing)

Indian share markets settled higher today taking cues from their Asian peers. At the closing bell, BSE Sensex ended up by 284 points.

Related Views on News

TORRENT PHARMA at 52 Week High; BSE 500 Index Up 1.0% (Market Updates)

Aug 17, 2018 | Updated on Aug 17, 2018

TORRENT PHARMA share price has hit a 52-week high. It is presently trading at Rs 1,770. BSE 500 Index is up by 1.0% at 15,508. Within the BSE 500, TORRENT PHARMA (up 4.2%) and EDELWEISS FINANCIAL (up 8.5%) are among the top gainers, while top losers are TECHNO ELECTRIC and ZENSAR TECHNOLOGIES.

DR. LAL PATHLABS LTD Surges by 7%; BSE HEALTHCARE Index Up 1.6% (Market Updates)

Aug 17, 2018 | Updated on Aug 17, 2018

DR. LAL PATHLABS LTD share price has surged by 7% and its current market price is Rs 1,040. The BSE HEALTHCARE is up by 1.6%. The top gainers in the BSE HEALTHCARE Index are DR. LAL PATHLABS LTD (up 7.4%) and CADILA HEALTHCARE (up 5.4%). The top losers are THYROCARE TECHNOLOGIES and SANOFI INDIA (down 0.2%).

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

This is a Must-Have Stock for Your Portfolio(The 5 Minute Wrapup)

Aug 8, 2018

Tanushree just released the permanent wealth blueprint report. This report includes three safe and steady stocks. I like one in particular. Here's why

Trading in These Times: 8% Gains in 3 Days!(Profit Hunter)

Aug 9, 2018

Here are 2 stocks you can buy right now! And there are plenty more opportunities to come...

Banks are Raising FD Rates and That's Good News(Vivek Kaul's Diary)

Aug 7, 2018

Lending to the retail segment remains strong, whereas lending to the service sector has picked up dramatically.

Why HDFC Equity Fund Disappointed Its Investors(Outside View)

Aug 9, 2018

Though popular, HDFC Equity Fund is not among the best performers anymore. Here is the reason behind its underperformance that has left investors disappointed.

HDFC AMC Makes 65% Listing Gains! Should It Attract Mutual Fund Investors?(Outside View)

Aug 8, 2018

PersonalFN explains if investors should invest in schemes of HDFC Mutual Fund looking at the listing gains of HDFC AMC.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

TORRENT PHARMA SHARE PRICE


Aug 17, 2018 (Close)

TRACK TORRENT PHARMA

  • Track your investment in TORRENT PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON TORRENT PHARMA

TORRENT PHARMA 8-QTR ANALYSIS

COMPARE TORRENT PHARMA WITH

MARKET STATS